How many institutions held BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 in Q2 2023?

83 institutional investors reported BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 for Q2 2023. Use the holders table for investor-level position and value details.

BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI)

Q: What does CUSIP 09075P105 represent in this 13F holders report?

CUSIP 09075P105 is the security identifier for BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 used to aggregate holder disclosures.

CUSIP: 09075P105

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class: Equity / Common Stock, par value $0.001
Shares outstanding: 26,011,000
Total 13F shares: 17,642,933
Share change: +280,882
Total reported value: $117,491,802
Put/Call ratio: 126%
Price per share: $6.66
Number of holders: 83
Value change: -$7,226,324
Number of buys: 48
Number of sells: 43

Quarterly Holders Quick Answers

What is CUSIP 09075P105?
CUSIP 09075P105 identifies BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2023
Previous quarter: Q1 2023

Recent filing periods for CUSIP 09075P105:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Rashmi Agarwal	3/4/5	10%+ Owner	— class O/S missing	8,554,945	$187,267,747	—	03 Apr 2023	3/4/5
Vipin Agarwal	3/4/5	10%+ Owner	— class O/S missing	8,554,945	$187,267,747	—	03 Apr 2023	3/4/5
Indu R. Gupta	3/4/5	10%+ Owner	— class O/S missing	8,550,396	$187,168,169	—	03 Apr 2023	3/4/5
Tarun K. Gupta	3/4/5	10%+ Owner	— class O/S missing	8,550,396	$187,168,169	—	03 Apr 2023	3/4/5
Suganthi Balasubramanian	3/4/5	10%+ Owner	— class O/S missing	8,547,750	$187,110,248	—	03 Apr 2023	3/4/5
Anita Jain	3/4/5	10%+ Owner	— class O/S missing	8,547,300	$187,100,398	—	03 Apr 2023	3/4/5
Diwakar Jain	3/4/5	10%+ Owner	— class O/S missing	8,547,300	$187,100,398	—	03 Apr 2023	3/4/5
Krishnan Nandabalan	3/4/5	Director, 10%+ Owner	— mixed-class rows	8,840,750 mixed-class rows	$187,088,358	—	06 Apr 2023	3/4/5
Akrati Agarwal	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Alka Sood	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Anesha Agarwal	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Bina Jatin Patel	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
BioXcel Holdings, Inc.	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	25 Jun 2021	3/4/5
BioXcel LLC	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	25 Jun 2021	3/4/5
Jatin Markand Patel	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Krunal Dilip Patel	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Marshal D. Gibson	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Michael James Aiello	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
Pardeep Kumar Sood	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	03 Apr 2023	3/4/5
FMR LLC	13F	Company	16%	4,276,693	$79,803,091	—	31 Mar 2023	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	8%	2,081,979	$38,849,728	—	31 Mar 2023	13F
STATE STREET CORP	13F	Company	6.8%	1,760,683	$32,854,345	—	31 Mar 2023	13F
BlackRock Finance, Inc.	13F	Company	5.3%	1,370,688	$25,577,038	—	31 Mar 2023	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	5.1%	1,334,606	$24,903,748	—	31 Mar 2023	13F
VANGUARD GROUP INC	13F	Company	4.1%	1,063,974	$19,853,756	—	31 Mar 2023	13F
Artemis Investment Management LLP	13F	Company	3.8%	981,472	$18,278,606	—	31 Mar 2023	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	1.5%	388,765	$7,254,355	—	31 Mar 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.5%	383,129	$7,149,187	—	31 Mar 2023	13F
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	13F	Company	1.4%	364,086	$6,793,845	—	31 Mar 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	1.3%	340,925	$6,361,660	—	31 Mar 2023	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.84%	217,991	$4,067,712	—	31 Mar 2023	13F
NORTHERN TRUST CORP	13F	Company	0.81%	211,665	$3,949,669	—	31 Mar 2023	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.63%	163,650	$3,053,710	—	31 Mar 2023	13F
UBS Group AG	13F	Company	0.62%	160,289	$2,990,993	—	31 Mar 2023	13F
Rafferty Asset Management, LLC	13F	Company	0.57%	149,112	$2,782,430	—	31 Mar 2023	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.55%	143,893	$2,685,043	—	31 Mar 2023	13F
Ikarian Capital, LLC	13F	Company	0.51%	133,014	$2,482,041	—	31 Mar 2023	13F
MORGAN STANLEY	13F	Company	0.5%	130,089	$2,427,461	—	31 Mar 2023	13F
CITIGROUP INC	13F	Company	0.46%	118,975	$2,220,074	—	31 Mar 2023	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.44%	113,770	$2,122,948	—	31 Mar 2023	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.36%	94,000	$1,754,000	—	31 Mar 2023	13F
CITADEL ADVISORS LLC	13F	Company	0.32%	84,432	$1,575,501	—	31 Mar 2023	13F
DAVENPORT & Co LLC	13F	Company	0.31%	80,295	$1,498,305	—	31 Mar 2023	13F
Bank of New York Mellon Corp	13F	Company	0.3%	77,132	$1,439,283	—	31 Mar 2023	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.24%	61,981	$1,156,565	—	31 Mar 2023	13F
FEDERATED HERMES, INC.	13F	Company	0.24%	61,730	$1,151,882	—	31 Mar 2023	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.24%	61,432	$1,146,282	—	31 Mar 2023	13F
Nuveen Asset Management, LLC	13F	Company	0.24%	61,340	$1,145,000	—	31 Mar 2023	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.22%	57,400	$1,071,084	—	31 Mar 2023	13F
BARCLAYS PLC	13F	Company	0.22%	56,023	$1,045,389	—	31 Mar 2023	13F

Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) as of Q2 2023

As of 30 Jun 2023, BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) was held by 83 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 17,642,933 shares. The largest 10 holders included FMR LLC, STATE STREET CORP, ADAGE CAPITAL PARTNERS GP, L.L.C., BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, Artemis Investment Management LLP, MASSACHUSETTS FINANCIAL SERVICES CO /MA/, GEODE CAPITAL MANAGEMENT, LLC, and AMERIPRISE FINANCIAL INC. This page lists 83 institutional shareholders reporting positions in this security for the Q2 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Q2 2023 holders

Holder diff

-13

Investor	Q1 2023 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q1 2023 Value $	Q2 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.